

TiGenix publishes transparency notifications pursuant to Article 14 of the Law of May 2, 2007

Leuven (Belgium) – August 2, 2013 – TiGenix NV (Euronext Brussels: TIG) publishes today transparency notifications pursuant to Article 14 of the Belgian Law of May 2, 2007 regarding the publication of major holdings in issuers whose securities are admitted to trading on a regulated market and including various provisions.

It concerns the following notifications:

1. Notification by the company MM Asset Management Inc (with address at 120 Adelaide Street West, Suite 2601, Box 35, Toronto, Ontario M5H 1T1, Canada), who notifies alone, regarding the crossing above the 3% threshold on July 24, 2013 by MM Asset Management Inc following the acquisition of shares. On July 24, 2013, this company held 4,000,000 shares (3.29%) (compared to the denominator of 121,547,678 shares on July 24, 2013).

MM Asset Management Inc is the management company of MMCAP International Inc SPC (a Cayman Islands investment fund). MM Asset Management Inc exercises the voting rights attached to the shares owned by MMCAP International Inc SPC at its own discretion in the absence of specific instructions.

MM Asset Management Inc is not controlled.

2. Notification by Mr. Steven Verraes (with address at Kastanjedreef 6, 8510 Rollegem, Belgium), who notifies alone, regarding the crossing above the 3% threshold on July 24, 2013 following the acquisition of shares. On July 24, 2013, Mr. Steven Verraes held 4,000,000 shares (3.29%) (compared to the denominator of 121,547,678 shares on July 24, 2013).
3. Notification by the related companies Novartis AG (with address at Lichtstrasse 35, 4056 Basel, Switzerland) / Novartis Bioventures Ltd (with address at Front Street 131, Hamilton, HM, 12 Bermuda), following the passive crossing below the 5% threshold on July 24, 2013 by the group as a whole, after which the participations of these companies were as follows (compared to the denominator of 121,547,678 shares on July 24, 2013) (number of shares held unchanged compared to previous notification; percentage decreased due to higher total number of outstanding shares):
 - Novartis AG: 0 shares(0%),
 - Novartis Bioventures Ltd: 5,534,905 shares (4.55%),
 - Total: 5,534,905 shares (4.55%).

The chain of controlled undertakings through which the holdings are effectively held, is as follows: Novartis AG controls Novartis Bioventures Ltd.

4. Notification by the related companies Roche Holding AG (with address at Grenzacherstrasse 124, 4058 Basel, Switzerland) / Roche Finanz AG (with address at Grenzacherstrasse 122, 4058 Basel, Switzerland), following the passive crossing below the 5% threshold on July 24, 2013 by the group as a whole and the transfer of shares by Roche Finanz AG (which previously held 5,534,905 shares), after which the participations of these companies were as follows (compared to the denominator of 121,547,678 shares on July 24, 2013):
- Roche Holding AG: 0 shares (0%),
 - Roche Finanz AG: 5,261,446 shares (4.33%),
 - Total: 5,261,446 shares (4.33%).

The chain of controlled undertakings through which the holdings are effectively held, is as follows: Roche Holding AG controls Roche Finanz AG.

5. Notifications by the company Ventech SA (with address at avenue de l'Opéra 47, 75002 Paris, France), who notifies alone:
- a) Passive crossing below the 5% threshold on July 24, 2013, after which the company held 4.27% of the shares (or: 5,195,199 shares compared to the denominator of 121,547,678 shares on July 24, 2013); and.
 - b) Crossing below the 3% threshold on July 29, 2013 following the transfer of shares, after which the company held 956,392 shares (0.76%) (compared to the denominator of 126,288,586 shares on July 26, 2013).

Ventech S.A. is the management company of FCPR Ventech Capital III (a collective investment undertaking within the meaning of Article 9, §2 of the Royal Decree of February 14, 2008) and exercises the voting rights attached to the shares owned by this fund at its own discretion.

Ventech SA is not controlled.

6. Notification by the related persons LRM NV / Mijnen NV (both with address at Kempischesteenweg 555, 3500 Hasselt, Belgium) / Flemish Region (with address at Martelaarsplein 7, 1000 Brussels, Belgium), following the passive crossing below the lowest threshold of 3% on July 24, 2013 by the group as a whole, after which the participations of these persons were as follows (compared to the denominator of 121,547,678 shares on July 24, 2013) (number of shares held unchanged compared to previous notification; percentage decreased due to higher total number of outstanding shares):
- Mijnen NV: 3,000,000 shares (2.47%),
 - LRM NV: 200,000 shares (0.16%),
 - Flemish Region: 0 shares (0%),
 - Total: 3,200,000 shares (2.63%).

The chain of controlled undertakings through which the holdings are effectively held, is as follows: Mijnen NV is controlled by LRM NV. LRM NV is controlled by the Flemish Region.

For further details regarding these notifications, we refer to our website: <http://www.tigenix.com/en/page/26/shareholders>.

For more information:

Eduardo Bravo
Chief Executive Officer
eduardo.bravo@tigenix.com

TIGENIX

Claudia D'Augusta
Chief Financial Officer
claudia.daugusta@tigenix.com

Hans Herklots
hans.herklots@tigenix.com
+32 16 39 60 97

About TiGenix

TiGenix NV (Euronext Brussels: TIG) is a leading European cell therapy company with a marketed product for cartilage repair, ChondroCelect®, and a strong pipeline with clinical stage allogeneic adult stem cell programs for the treatment of autoimmune and inflammatory diseases. TiGenix is based out of Leuven (Belgium) and has operations in Madrid (Spain), and Sittard-Geleen (the Netherlands). For more information please visit www.tigenix.com.